A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide

Journal of Virology

Volumn 89, Issue 23, 2015, Pages 11945-11953

  Kaneko, Manabu ^a,b   Watashi, Koichi ^a,b   Kamisuki, Shinji ^b,j   Matsunaga, Hiroki ^b   Iwamoto, Masashi ^a,b   Kawai, Fumihiro ^c   Ohashi, Hirofumi ^a,b   Tsukuda, Senko ^a,d   Shimura, Satomi ^a,e,k   Suzuki, Ryosuke ^a   Aizaki, Hideki ^a   Sugiyama, Masaya ^f   Park, Sam Yong ^c   Ito, Takayoshi ^g   Ohtani, Naoko ^b   Sugawara, Fumio ^b   Tanaka, Yasuhito ^h   Mizokami, Masashi ^f   Sureau, Camille ⁱ   Wakita, Takaji ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d RIKEN   (Japan)

^e Scynexis Inc   (United States)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

^h NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

ⁱ INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^j AZABU UNIVERSITY   (Japan)

^k ETH ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; SODIUM BILE ACID COTRANSPORTER; UNCLASSIFIED DRUG; VANITARACIN A; COTRANSPORTER; MOLECULAR LIBRARY; ORGANIC ANION TRANSPORTER; POLYKETIDE; PRIMER DNA; SODIUM-BILE ACID COTRANSPORTER;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HEPATITIS B; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; LUMINESCENCE; METABOLISM; MOLECULAR LIBRARY; PHYSIOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; TALAROMYCES;

CELL LINE; DNA PRIMERS; DRUG DISCOVERY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMANS; LUMINESCENT MEASUREMENTS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; POLYKETIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE; SYMPORTERS; TALAROMYCES; VIRUS INTERNALIZATION;

EID: 84949674768     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01855-15     Document Type: Article

References (54)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212-2219. http://dx.doi.org/10.1016/j.vaccine.2011.12.116.
2. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trepo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barre-Sinoussi F, Delfraissy JF, Zoulim F. 2015. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 64:1314-1326. http://dx.doi.org/10.1136/gutjnl-2014-308943.
3. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. 2008. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134:405-415. http://dx.doi.org/10.1053/j.gastro.2007.11.036.
4. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. 2012. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122:529-537. http://dx.doi.org/10.1172/JCI58847.
5. Tenney D, Levine S, Rose R, Walsh A, Weinheimer S, Discotto L, Plym M, Pokornowski K, Yu C, Angus P. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48:3498-3507.http://dx.doi.org/10.1128/AAC.48.9.3498-3507.2004.
6. Anwer MS, Stieger B. 2014. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch 466:77-89. http://dx.doi.org/10.1007/s00424-013-1367-0.
7. Klaassen CD, Aleksunes LM. 2010. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96. http://dx.doi.org/10.1124/pr.109.002014.
8. Stieger B. 2011. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011:205-259.http://dx.doi.org/10.1007/978-3-642-14541-4_5.
9. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049. http://dx.doi.org/10.7554/eLife.00049.
10. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, Urban S. 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:1070-1083.http://dx.doi.org/10.1053/j.gastro.2013.12.024.
11. Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. 2014. Entry of hepatitis B and C viruses-recent progress and future impact. Curr Opin Virol 4:58-65. http://dx.doi.org/10.1016/j.coviro.2013.12.002.
12. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. 2009. Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581-592. http://dx.doi.org/10.1016/j.jhep.2009.05.022.
13. Tong S, Li J. 2014. Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning? Gastroenterology 146: 902-905. http://dx.doi.org/10.1053/j.gastro.2014.02.024.
14. Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T. 2014. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun 443:808-813. http://dx.doi.org/10.1016/j.bbrc.2013.12.052.
15. Cragg GM, Newman DJ. 2013. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830:3670-3695. http://dx.doi.org/10.1016/j.bbagen.2013.02.008.
16. Newman DJ, Cragg GM. 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311-335. http://dx.doi.org/10.1021/np200906s.
17. Ogura N, Watashi K, Noguchi T, Wakita T. 2014. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line. Biochem Biophys Res Commun 452: 315-321. http://dx.doi.org/10.1016/j.bbrc.2014.08.029.
18. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
19. Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M, Li J, Tong S, Wakita T. 2015. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem 290:5673-5684. http://dx.doi.org/10.1074/jbc. M114.602540.
20. Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T. 2013. Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem 288:31715-31727. http://dx.doi.org/10.1074/jbc. M113.501122.
21. Myobatake Y, Takemoto K, Kamisuki S, Inoue N, Takasaki A, Takeuchi T, Mizushina Y, Sugawara F. 2014. Cytotoxic alkylated hydroquinone, phenol, and cyclohexenone derivatives from Aspergillus violaceofuscus Gasperini. J Nat Prod 77:1236-1240. http://dx.doi.org/10.1021/np401017g.
22. Nakajima S, Watashi K, Kamisuki S, Tsukuda S, Takemoto K, Matsuda M, Suzuki R, Aizaki H, Sugawara F, Wakita T. 2013. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives. Biochem Biophys Res Commun 440:515-520. http://dx.doi.org/10.1016/j.bbrc.2013.09.100.
23. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633-642. http://dx.doi.org/10.1084/jem.20021756.
24. Kuo MY, Chao M, Taylor J. 1989. Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol 63:1945-1950.
25. Sureau C, Guerra B, Lee H. 1994. The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus. J Virol 68: 4063-4066.
26. Gudima S, Meier A, Dunbrack R, Taylor J, Bruss V. 2007. Two potentially important elements of the hepatitis B virus large envelope protein are dispensable for the infectivity of hepatitis delta virus. J Virol 81:4343-4347.http://dx.doi.org/10.1128/JVI.02478-06.
27. Gripon P, Cannie I, Urban S. 2005. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79:1613-1622. http://dx.doi.org/10.1128/JVI.79.3.1613-1622.2005.
28. Glebe D, Urban S, Knoop EV, Cag N, Krass P, Grun S, Bulavaite A, Sasnauskas K, Gerlich WH. 2005. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 129:234-245. http://dx.doi.org/10.1053/j.gastro.2005.03.090.
29. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. 1999. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol 73:2052-2057.
30. Leistner CM, Gruen-Bernhard S, Glebe D. 2008. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 10: 122-133.
31. Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:1759-1768. http://dx.doi.org/10.1002/hep.21896.
32. Blanchet M, Sureau C, Labonte P. 2014. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antiviral Res 106:111-115. http://dx.doi.org/10.1016/j.antiviral.2014.03.017.
33. Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS. The FDA approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir Ther http://dx.doi.org/10.3851/IMP2965.
34. Lucifora J, Esser K, Protzer U. 2013. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res 97:195-197. http://dx.doi.org/10.1016/j.antiviral.2012.12.008.
35. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. 2014. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60:723-731. http://dx.doi.org/10.1016/j.jhep.2013.11.022.
36. Wang XJ, Hu W, Zhang TY, Mao YY, Liu NN, Wang SQ. 2015. Irbesartan, anFDAapproved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. Antiviral Res 120:140-146. http://dx.doi.org/10.1016/j.antiviral.2015.06.007.
37. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T. 2014. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59:1726-1737. http://dx.doi.org/10.1002/hep.26982.
38. Taylor JM. 2013. Virus entry mediated by hepatitis B virus envelope proteins. World J Gastroenterol 19:6730-6734. http://dx.doi.org/10.3748/wjg.v19.i40.6730.
39. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. 2006. Time-and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80:1734-1741. http://dx.doi.org/10.1128/JVI.80.4.1734-1741.2006.
40. Matsunaga H, Kamisuki S, Kaneko M, Yamaguchi Y, Takeuchi T, Watashi K, Sugawara F. 2015. Isolation and structure of vanitaracin A, a novel anti-hepatitis B virus compound from Talaromyces sp. Bioorg Med Chem Lett 25:4325-4328. http://dx.doi.org/10.1016/j.bmcl.2015.07.067.
41. Calland N, Dubuisson J, Rouille Y, Seron K. 2012. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses 4:2197-2217. http://dx.doi.org/10.3390/v4102197.
42. Jiang Y, Ng TB, Wang CR, Zhang D, Cheng ZH, Liu ZK, Qiao WT, Geng YQ, Li N, Liu F. 2010. Inhibitors from natural products to HIV-1 reverse transcriptase, protease and integrase. Mini Rev Med Chem 10: 1331-1344. http://dx.doi.org/10.2174/138955710793564133.
43. Son M, Lee M, Sung GH, Lee T, Shin YS, Cho H, Lieberman PM, Kang H. 2013. Bioactive activities of natural products against herpesvirus infection. J Microbiol 51:545-551. http://dx.doi.org/10.1007/s12275-013-3450-9.
44. Sun F, Huang R. 2014. The medicinal potential of natural products for the development of anti-influenza agents. Curr Drug Targets 15:175-183. http://dx.doi.org/10.2174/13894501113146660203.
45. Zhou X, Liu J, Yang B, Lin X, Yang XW, Liu Y. 2013. Marine natural products with anti-HIV activities in the last decade. Curr Med Chem 20:953-973. http://dx.doi.org/10.2174/092986713805219118.
46. Urban S, Bartenschlager R, Kubitz R, Zoulim F. 2014. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147: 48-64. http://dx.doi.org/10.1053/j.gastro.2014.04.030.
47. Fofana I, Jilg N, Chung RT, Baumert TF. 2014. Entry inhibitors and future treatment of hepatitis C. Antiviral Res 104:136-142. http://dx.doi.org/10.1016/j.antiviral.2014.02.001.
48. Lindenbach BD, Rice CM. 2013. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11:688-700. http://dx.doi.org/10.1038/nrmicro3098.
49. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26:335-341. http://dx.doi.org/10.1038/nbt1389.
50. Huang HC, Tao MH, Hung TM, Chen JC, Lin ZJ, Huang C. 2014. ()-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res 111:100-111. http://dx.doi.org/10.1016/j.antiviral.2014.09.009.
51. Barrera A, Guerra B, Notvall L, Lanford RE. 2005. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol 79:9786-9798. http://dx.doi.org/10.1128/JVI.79.15.9786-9798.2005.
52. Ciancio A, Rizzetto M. 2014. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol 11:68-71. http://dx.doi.org/10.1038/nrgastro.2013.164.
53. Taylor JM. 2012. Virology of hepatitis D virus. Semin Liver Dis 32:195-200.http://dx.doi.org/10.1055/s-0032-1323623.
54. Wedemeyer H, Manns MP. 2010. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31-40. http://dx.doi.org/10.1038/nrgastro.2009.205.